Your browser doesn't support javascript.
loading
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy.
Bai, Xue; Hu, Jiani; Betof Warner, Allison; Quach, Henry T; Cann, Christopher G; Zhang, Michael Z; Si, Lu; Tang, Bixia; Cui, Chuanliang; Yang, Xiaoling; Wei, Xiaoting; Pallan, Lalit; Harvey, Catriona; Manos, Michael P; Ouyang, Olivia; Kim, Michelle S; Kasumova, Gyulnara; Cohen, Justine V; Lawrence, Donald P; Freedman, Christine; Fadden, Riley M; Rubin, Krista M; Sharova, Tatyana; Frederick, Dennie T; Flaherty, Keith T; Rahma, Osama E; Long, Georgina V; Menzies, Alexander M; Guo, Jun; Shoushtari, Alexander N; Johnson, Douglas B; Sullivan, Ryan J; Boland, Genevieve M.
Affiliation
  • Bai X; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
  • Hu J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Betof Warner A; Department of Data Sciences (Division of Biostatistics), Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Quach HT; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.
  • Cann CG; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Zhang MZ; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Si L; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Tang B; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
  • Cui C; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
  • Yang X; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
  • Wei X; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
  • Pallan L; Department of Medical Oncology, Shanxi Bethune Hospital, Shanxi, China.
  • Harvey C; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
  • Manos MP; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Ouyang O; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Kim MS; Center for Immune-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Kasumova G; Center for Immune-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Freedman C; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Fadden RM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Rubin KM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Sharova T; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Frederick DT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Flaherty KT; Department of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Rahma OE; Department of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Long GV; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Menzies AM; Senior authors at each site.
  • Guo J; Center for Immune-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Shoushtari AN; Senior authors at each site.
  • Johnson DB; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Sullivan RJ; Senior authors at each site.
  • Boland GM; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.
Clin Cancer Res ; 27(21): 5993-6000, 2021 11 01.
Article in En | MEDLINE | ID: mdl-34376536
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immune Checkpoint Inhibitors / Glucocorticoids / Melanoma Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2021 Document type: Article Affiliation country: China Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immune Checkpoint Inhibitors / Glucocorticoids / Melanoma Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2021 Document type: Article Affiliation country: China Country of publication: Estados Unidos